SecBot SecBot

Drug Origin Transparency Act of 2023

H.R. 3810 Rep. ANNA ESHOO (D-CA-16) In committee
Bill text PDF
  1. Introduced Jun 5
  2. Committee Jun 5
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Jun 5, 2023Next: House vote
1237d ago Jun 9, 2023: Referred to the Subcommittee on Health.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 1 filing
Subscribe to see spend
Member trades
3trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Financials 1
Search all 1 companies, their asks and price moves Subscribe

Summary

Drug Origin Transparency Act of 2023

Full summary2 paragraphs

This bill requires drug manufacturers to report on the suppliers of ingredients used in their products.

Specifically, drug manufacturers must report information relating to the supply chain of their products, including the suppliers of active ingredients and the amount of drugs that are manufactured using those ingredients. Drug manufacturers must also include information about the manufacturers of ingredients on the labels of their products.

Library of Congress summary, Jun 5, 2023

Summary versions
  • Introduced in HouseJun 5, 2023

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.